Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein.
Yang Z, Loy J, Poirson B, Dai Y, Rajendran S, Xu S, Spires V, Gururajan M, Lin Z, Arbanas J, Carl S, Pace S, Wang Y, Mehl J, Vasudevan K, Spires T, Novosiadly R, Coker S, Perez R, Covello K, Morin P, Graziano R, Broz M, Lehman-McKeeman L. Yang Z, et al. Among authors: loy j. Front Pharmacol. 2022 Jun 20;13:829063. doi: 10.3389/fphar.2022.829063. eCollection 2022. Front Pharmacol. 2022. PMID: 35795558 Free PMC article.
Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active Doses.
Yang Z, Rajendran S, Spires V, Poirson B, Gururajan M, Lin Z, Arbanas J, Krystek S, Loy J, Cheng Y, Carl S, Pace S, Wang Y, Mehl J, Xu S, Vasudevan K, Broz M, Lehman-McKeeman L, Morin P, Graziano RF. Yang Z, et al. Among authors: loy j. Drug Metab Dispos. 2022 Jul;50(7):898-908. doi: 10.1124/dmd.121.000799. Epub 2022 May 11. Drug Metab Dispos. 2022. PMID: 35545256
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
Sun LQ, Mull E, Zheng B, D'Andrea S, Zhao Q, Wang AX, Sin N, Venables BL, Sit SY, Chen Y, Chen J, Cocuzza A, Bilder DM, Mathur A, Rampulla R, Chen BC, Palani T, Ganesan S, Arunachalam PN, Falk P, Levine S, Chen C, Friborg J, Yu F, Hernandez D, Sheaffer AK, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Ng A, Mueller L, Grasela DM, Adams S, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Wang YK, Fang H, Cockett MI, Meanwell NA, McPhee F, Scola PM. Sun LQ, et al. Among authors: loy j. J Med Chem. 2016 Sep 8;59(17):8042-60. doi: 10.1021/acs.jmedchem.6b00821. Epub 2016 Aug 26. J Med Chem. 2016. PMID: 27564532
Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
Alt A, Pendri A, Bertekap RL Jr, Li G, Benitex Y, Nophsker M, Rockwell KL, Burford NT, Sum CS, Chen J, Herbst JJ, Ferrante M, Hendricson A, Cvijic ME, Westphal RS, O'Connell J, Banks M, Zhang L, Gentles RG, Jenkins S, Loy J, Macor JE. Alt A, et al. Among authors: loy j. J Pharmacol Exp Ther. 2016 Feb;356(2):293-304. doi: 10.1124/jpet.115.226910. Epub 2015 Nov 18. J Pharmacol Exp Ther. 2016. PMID: 26582730
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies.
Easton A, Jensen ML, Wang C, Hagedorn PH, Li Y, Weed M, Meredith JE, Guss V, Jones K, Gill M, Krause C, Brown JM, Hunihan L, Natale J, Fernandes A, Lu Y, Polino J, Bookbinder M, Cadelina G, Benitex Y, Sane R, Morrison J, Drexler D, Mercer SE, Bon C, Pandya NJ, Jagasia R, Ou Yang TH, Distler T, Grüninger F, Meldgaard M, Terrigno M, Macor JE, Albright CF, Loy J, Hoeg AM, Olson RE, Cacace AM. Easton A, et al. Among authors: loy j. Mol Ther Nucleic Acids. 2022 Aug 4;29:625-642. doi: 10.1016/j.omtn.2022.07.027. eCollection 2022 Sep 13. Mol Ther Nucleic Acids. 2022. PMID: 36090761 Free PMC article.
Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, Polson CT, Wang J, Roberts SB, Hendrick JP, Anderson JJ, Loy JK, Denton R, Verdoorn TA, Smith DW, Felsenstein KM. Barten DM, et al. Among authors: loy jk. J Pharmacol Exp Ther. 2005 Feb;312(2):635-43. doi: 10.1124/jpet.104.075408. Epub 2004 Sep 27. J Pharmacol Exp Ther. 2005. PMID: 15452193
Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.
Balsitis S, Gali V, Mason PJ, Chaniewski S, Levine SM, Wichroski MJ, Feulner M, Song Y, Granaldi K, Loy JK, Thompson CM, Lesniak JA, Brockus C, Kishnani N, Menne S, Cockett MI, Iyer R, Mason SW, Tenney DJ. Balsitis S, et al. Among authors: loy jk. PLoS One. 2018 Feb 14;13(2):e0190058. doi: 10.1371/journal.pone.0190058. eCollection 2018. PLoS One. 2018. PMID: 29444087 Free PMC article.
Oncostatin M: development of a pleiotropic cytokine.
Loy JK, Davidson TJ, Berry KK, Macmaster JF, Danle B, Durham SK. Loy JK, et al. Toxicol Pathol. 1999 Mar-Apr;27(2):151-5. doi: 10.1177/019262339902700201. Toxicol Pathol. 1999. PMID: 10207978 Review.
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.
Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, D'Andrea SV, Zheng B, Hewawasam P, Tu Y, Friborg J, Falk P, Hernandez D, Levine S, Chen C, Yu F, Sheaffer AK, Zhai G, Barry D, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Good AC, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Mueller L, Colonno RJ, Grasela DM, Adams SP, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Meanwell NA, McPhee F. Scola PM, et al. Among authors: loy j. J Med Chem. 2014 Mar 13;57(5):1730-52. doi: 10.1021/jm500297k. Epub 2014 Mar 5. J Med Chem. 2014. PMID: 24564672
225 results